In today's ACT Brief, we examine practical guidance for clinical operations teams beginning AI adoption, how hierarchical endpoints better reflect treatment benefit, and why early-stage program failures signal smarter pipeline management.
News|Podcasts|October 6, 2026
ACT Brief: Ibogaine Trial Design Guidance, Outsourcing Model Oversight Gaps, and Kidney Disease Partnership
Author(s)Andy Studna, Senior Editor
In today's ACT Brief, we examine FDA input sought on early-phase ibogaine protocols, why mixed outsourcing models spread faster than oversight infrastructure, and a major partnership for a rare kidney disease treatment.
This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.
- In a
new request for information , the FDA is seeking public input on approaches to early-phase clinical trial design for ibogaine drug products, including dose selection and escalation, care setting, safety monitoring, eligibility criteria, stopping rules, and safety oversight. Comments are due by November 20, 2026, as part of a whole-of-government effort following the Trump administration's April 2026 executive order on accelerating research into psychedelic medicines for serious mental illness. - In a
new FAQ , we examined how mixed outsourcing models combining full-service providers and functional service providers are gaining ground as sponsors seek agility and resource flexibility. However, the oversight infrastructure, audit trails, and accountability structures needed to run these models well and survive regulatory inspection are consistently lagging behind adoption of the model itself. CSL and Alentis Therapeutics announced a global partnership to co-develop and co-promote lixudebart , with CSL paying $355 million upfront plus up to $1.2 billion in milestone payments. Lixudebart is a first-in-class therapy targeting claudin-1 for kidney and liver diseases, currently being evaluated in Phase II trials in patients with rapidly progressive kidney inflammation, with CSL funding completion of Phase II testing and planned Phase III trials across multiple indications.
That's all for today's ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.
Related to this article
In today's ACT Brief, we examine how AI enables sponsors to pressure-test protocols before enrollment, HHS's multi-initiative effort to accelerate trial design and execution, and FDA approval expanding heart disease therapy to adolescents.
In today's ACT Brief, we examine AI's role as trial design advisor with human leadership, how to govern autonomous agents in regulated operations, and real-world outcomes from switching to oral weight-loss therapy.
In today's ACT Brief, we examine how data drives honest enrollment assumptions, why RWE infrastructure lags ambition, and the disconnect between FDA rulemaking and enforcement on compounded therapies.
In today's ACT Brief, we examine what AI simulations surface in trial design, how RBQM delivers measurable financial returns, and three new FDA-approved treatments across hair loss, movement disorder, and bone disease.
In today's ACT Brief, we examine how AI is surfacing endpoint options beyond traditional design thinking, why sponsor oversight of outsourced work often fails on inspection despite being robust in practice, and a new combination drug for advanced kidney cancer.
In today's ACT Brief, we examine what patient-site relationships need beyond easier technology, how to build defensible rare disease evidence from scratch, and how real-world data and AI improve enrollment screening accuracy.
In today's ACT Brief, we examine why defensible trial data depends on traceability and platform ownership, what CGT site readiness requires as therapy moves to community care, and why data harmonization is AI's primary bottleneck.
Trending on Applied Clinical Trials Online
1
HHS Launches SURPASS Program and Three Complementary Initiatives to Transform Clinical Trial Design and Infrastructure
2
Mixed Outsourcing Models Are Spreading. Is Sponsor Oversight Keeping Up?
3
FDA Seeks Public Input on Early-Phase Clinical Trial Design for Ibogaine
4
ACT Brief: AI Adoption Starting Points, Hierarchical Endpoints and Patient Priorities, and Early-Stage Program Termination
5